John Crowley, BIO CEO (BIO via website)

BIO CEO de­fends the or­ga­ni­za­tion's about-face on the Biose­cure Act

As the head of the trade group BIO and a par­ent to chil­dren with a rare dis­ease, John Crow­ley is per­son­al­ly and pro­fes­sion­al­ly at the cen­ter of a bill tar­get­ing Chi­nese biotechs.

Un­der Crow­ley, BIO switched its stance to sup­port the pro­posed Biose­cure Act that would es­sen­tial­ly ban WuXi AppTec and oth­er con­trac­tors that are ubiq­ui­tous in drug de­vel­op­ment. But among the com­pa­nies that have flagged sup­ply chain risks from the leg­is­la­tion is Am­i­cus Ther­a­peu­tics, a com­pa­ny found­ed by Crow­ley that de­vel­oped a rare dis­ease med­i­cine for his two chil­dren and oth­ers with Pompe dis­ease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.